Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: Radiolabeling and PET–MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer

Fig. 3

PET–MRI of 64Cu-MN-anti-miR10b uptake by metastatic lesions. a In vivo PET–MRI maximum intensity projection (MIP) images of mice bearing metastatic breast adenocarcinoma 24 h after injection of a microdose or a macrodose of 64Cu-MN-anti-miR10b. The yellow arrows point to bone or lymph node (LN) metastasis. b Quantitation of 64Cu-MN-anti-miR10b accumulation in metastatic (Mets+) and non-metastatic (Mets−) organs obtained from in vivo PET images at 24 h post-injection (%ID/cc). The high signal intensity in the metastatic organs compared to the non-metastatic organs confirms uptake of the therapeutic by the metastases. Open circles represent mice injected with a microdose and closed circles represent mice injected with a macrodose. c Ex vivo PET–MRI of bone and lymph node metastases. From left: in vivo BLI, ex vivo PET, and ex vivo white-light photograph of metastatic lesions. d Ex vivo biodistribution of 64Cu-MN-anti-miR10b as visualized by PET 48 h after microdose injection and 24 h after macrodose injection

Back to article page